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SUMMARY 1 
Connexin 30 (Cx30), a member of the large gap junction protein family, plays a role in 2 
the homeostasis of the epidermis and inner ear through gap junctional intercellular 3 
communication (GJIC).  Here, we investigated the underlying mechanisms of four autosomal 4 
dominant Cx30 gene mutations linked to hearing loss and/or various skin diseases.  First, the 5 
T5M mutant linked to non-syndromic hearing loss formed functional gap junction channels and 6 
hemichannels, similar to wild type Cx30.  The loss-of-function V37E mutant associated with 7 
Clouston syndrome or keratitis-ichthyosis-deafness syndrome was retained in the endoplasmic 8 
reticulum and significantly induced apoptosis.  The G59R mutant linked to Vohwinkel and Bart-9 
Pumphrey syndromes was retained primarily in the Golgi apparatus and exhibited loss of gap 10 
junction channel and hemichannel function, but did not cause cell death.  Lastly, the A88V 11 
mutant related to Clouston syndrome also significantly induced apoptosis, although through an 12 
endoplasmic reticulum-independent mechanism.  Collectively, we discovered that four unique 13 
Cx30 mutants may cause disease through different mechanisms that also likely include their 14 
selective transdominant effects on co-expressed connexins, highlighting the overall complexity 15 
of connexin-linked diseases and the importance of GJIC in disease prevention.   16 
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INTRODUCTION 1 
Gap junctions are clusters of specialized intercellular channels that regulate the direct 2 
exchange of ions and various hydrophilic cellular metabolites smaller than 1000 Da, a process 3 
known as gap junctional intercellular communication (GJIC) (Alexander and Goldberg, 2003).  4 
Two inter-docked connexons (hemichannels), one from each of two apposing cells, form a 5 
functional gap junction channel.  Each connexon is composed of six oligomerized connexin (Cx) 6 
subunits, and to date, the connexin family consists of 21 members in humans (Sohl and Willecke, 7 
2003; Sohl and Willecke, 2004).  Interestingly, while the primary function of gap junction 8 
channels is to facilitate intercellular communication, hemichannels have also been reported to 9 
exist and function at the cell surface in an undocked state, permitting the transfer of molecules 10 
between extracellular and intracellular environments (Anselmi et al., 2008; Burra and Jiang, 11 
2011; Tong et al., 2007).  Hemichannels formed from single or multiple types of connexins are 12 
termed homomeric and heteromeric, respectively, and gap junction channels are characterized as 13 
homotypic or heterotypic according to whether their channels are composed of the same or 14 
different connexons (Burra and Jiang, 2011).  Channel composition depends on the connexin 15 
expression profile of each cell and tissue type, as well as the natural compatibility of the 16 
connexins to intermix (Beyer et al., 2013; Burra and Jiang, 2011; Laird, 2006).   17 
Connexins are highly expressed in virtually all tissues in the human body, and GJIC plays 18 
an essential role in the regulation of cellular and physiological processes including proliferation, 19 
differentiation, apoptosis, growth and development (Alexander and Goldberg, 2003; Choudhry et 20 
al., 1997; Decrock et al., 2009; Kumar and Gilula, 1996; McLachlan et al., 2007).  In the inner 21 
ear and the skin, proper connexin expression and function directly relate to the maintenance of 22 
cochlear homeostasis and epidermal differentiation, respectively (Langlois et al., 2007; 23 
Wangemann, 2006; Zhao et al., 2006).  In the cochlea, Cx26, Cx29, Cx30, Cx31 and Cx43, 24 
found in the epithelial and connective tissue gap junction networks, play a crucial role in sound 25 
transduction.  Cx26, and possibly other connexins, are thought to be involved in the recycling of 26 
K+ through the supporting cells back to the endolymphatic space, for potential re-entry into 27 
sensory cells when activated by an acoustic stimulus (Kikuchi et al., 2000; Nickel and Forge, 28 
2008).  Interestingly, at least seven connexins, including Cx26, Cx30 and Cx43, are temporally 29 
and spatially expressed at the protein level in the human epidermis with overlapping distribution 30 
in the various non-cornified epidermal strata (Di et al., 2001; Kretz et al., 2004).  While GJIC 31 
plays an important role in epidermal differentiation, it is also critical to the wound healing 1 
process (Churko and Laird, 2013; Langlois et al., 2007).  Here we focus on Cx30, which in 2 
humans, is predominantly expressed in the inner ear and epidermis (Di et al., 2001; Nickel and 3 
Forge, 2008). 4 
Connexin mutations have been linked to a number of different diseases ranging from 5 
developmental disorders to congenital cataracts (Laird, 2006).  Mutations in the genes encoding 6 
Cx26, Cx30, Cx30.3 and Cx31 in particular have been linked predominantly to hearing loss and 7 
various skin diseases (Di et al., 2001).  Importantly, mutations in Cx30 and Cx26, the most 8 
predominant connexins in the inner ear (Hoang Dinh et al., 2009), are the leading cause of nearly 9 
half the cases of inherited prelingual non-syndromic hearing loss (Bitner-Glindzicz, 2002; Chang 10 
et al., 2009; Schutz et al., 2010; Wang et al., 2011).   In particular, seven distinct single amino 11 
acid substitutions in the 1st half of the coding sequence of Cx30 are responsible for hearing loss 12 
and/or skin disease.  The T5M (threonine to methionine at position 5) and A40V (alanine to 13 
valine at position 40) mutations have been linked to non-syndromic hearing loss as no other 14 
tissues or organs where Cx30 is expressed were affected (Grifa et al., 1999; Wang et al., 2011).  15 
Interestingly, hidrotic ectodermal dysplasia, commonly known as Clouston syndrome, is a skin 16 
disease distinctly linked to G11R (glycine to arginine at position 11) (Chen et al., 2010; 17 
Common et al., 2002; Zhang et al., 2003), V37E (valine to glutamic acid at position 37) 18 
(Common et al., 2002; Jan et al., 2004; Smith et al., 2002), D50N (aspartic acid to asparagine at 19 
position 50) (Baris et al., 2008) and A88V (alanine to valine at position 88) (Common et al., 20 
2002; Essenfelder et al., 2004) Cx30 mutations.  This rare disease has a founder effect within the 21 
French-Canadian population and is characterized by palmoplantar hyperkeratosis (PPK), nail 22 
dystrophies, and partial to complete alopecia (Kibar et al., 2000; Zhang et al., 2003).  In some 23 
patients, other symptoms like ocular and craniofacial abnormalities, hearing loss and abnormal 24 
sweating and cardiac findings have been reported (Christianson and Fourie, 1996; Fraser and Der 25 
Kaloustian, 2001; Lamartine et al., 2000).  Interestingly, one patient harbouring a V37E Cx30 26 
mutation was diagnosed with keratitis-ichthyosis-deafness (KID) syndrome commonly 27 
associated with Cx26 mutations.  This patient experienced Clouston syndrome-like symptoms, 28 
but also hearing impairment and vascularising keratitis (Jan et al., 2004).  Finally, a G59R 29 
mutation results in the development of classical Vohwinkel syndrome and Bart-Pumphrey 30 
syndrome (Nemoto-Hasebe et al., 2009), which are also diseases most commonly caused by 31 
mutations in Cx26 (Bakirtzis et al., 2003; Jan et al., 2004; Richard et al., 2004).  Both syndromes 1 
result in PPK and sensorineural hearing loss, however, Bart-Pumphrey syndrome can be 2 
distinguished by the formation of knuckle pads, while patients with Vohwinkel syndrome 3 
develop constriction bands that cause spontaneous auto-amputation of the digits (pseudoainhum) 4 
(Bakirtzis et al., 2003; Richard et al., 2004). 5 
Previously, studies on a few of the Cx30 disease-linked mutations have revealed reduced 6 
or abolished gap junction function, as the majority of mutant proteins are retained in subcellular 7 
compartments (Common et al., 2002; Essenfelder et al., 2004; Wang et al., 2011).  Typically, 8 
most connexins follow the traditional secretory pathway by folding in the endoplasmic reticulum 9 
(ER), oligomerizing into connexons either in the ER or Golgi apparatus and by employing 10 
microtubules for efficient trafficking to the plasma membrane (Koval, 2006; Laird, 2006).  11 
Disruptions to any stage of this connexin transport process can have detrimental cellular effects 12 
and commonly results in connexin-linked disease (Laird, 2006).   13 
Connexin mutations can lead to trafficking defects and their retention within the cell. In 14 
particular, intracellular accumulation of Cx50 and Cx31 mutants cause cell death associated with 15 
activation of ER stress signaling pathways (Alapure et al., 2012; Tattersall et al., 2009). Aberrant 16 
accumulation of misfolded secretory proteins in the ER triggers a process known as the unfolded 17 
protein response (UPR) (Malhotra and Kaufman, 2007).  Typically, quality control mechanisms 18 
involving chaperones in the ER facilitate the re-folding of misfolded proteins for export out of 19 
the ER (Groenendyk and Michalak, 2005).  The UPR involves the activation of three ER 20 
membrane-bound sensors (PERK, IRE1 and ATF6) that work collectively to attenuate protein 21 
translation, increase the folding capacity of the ER through the up-regulation of chaperone 22 
proteins, increase lipid synthesis and force misfolded proteins through an ER-associated 23 
degradation pathway to relieve ER stress and maintain cellular homeostasis (Malhotra and 24 
Kaufman, 2007).  Failure of these processes to reduce ER stress results in the induction of 25 
apoptosis (Groenendyk and Michalak, 2005; Rasheva and Domingos, 2009). 26 
Currently, it is poorly understood how Cx30 mutations manifest into syndromic and non-27 
syndromic diseases involving the skin and cochlea.  In the present study, we characterized four 28 
different Cx30 mutants, linked to non-syndromic hearing loss, Clouston syndrome, KID 29 
syndrome and Vohwinkel/Bart-Pumphrey syndromes to gain critical insight into the mechanisms 30 
behind these distinct disease manifestations.  Our results indicate that the T5M mutant associated 31 
with non-syndromic hearing loss formed functional gap junction channels, while the skin 1 
disease-linked mutants were primarily retained in intracellular compartments, reducing channel 2 
function.  In addition, since we showed that Clouston syndrome-linked mutants induced cell 3 
death in keratinocytes, we investigated the potential mechanisms that cause cell death. 4 
Surprisingly, the ER-localized V37E mutant, did not substantially and consistently increase the 5 
expression of classical UPR markers, as would be predicted for misfolded proteins accumulating 6 
in the ER. However, V37E along with A88V mutant, activated a caspase-3 cleavage pathway to 7 
induce apoptosis. Finally, we demonstrated that skin disease-linked mutants are not rescued by 8 
co-expressed wild-type (wt) Cx30 or Cx26 in rat epidermal keratinocytes (REKs), and in 9 
particular, mutants associated with Clouston syndrome exhibit dominant-negative properties on 10 
these co-expressed connexins.  Collectively, these studies demonstrate the complexity of the 11 
mechanisms involved in connexin-linked diseases, as one Cx30 mutant even exhibited 12 
intercellular channel and hemichannel function, yet still causes disease.   13 
 14 
RESULTS 15 
Cx30 mutations linked to skin disease and non-syndromic hearing loss, and their 16 
differential ectopic expression and localization in REKs – Cx30 is a 261 amino acid gap 17 
junction protein that exhibits the topological structure of a typical connexin, with four 18 
transmembrane domains, two extracellular loops, one intracellular loop and cytoplasmic-exposed 19 
amino and carboxy termini (Fig. 1A).  The location of four distinct mutations that cause skin 20 
disease and/or hearing loss are all located within the 1st half of the Cx30 protein (Fig. 1A). 21 
Western blot analysis was used to determine the expression levels of green fluorescent 22 
protein (GFP)-tagged T5M, V37E, G59R and A88V mutants in REKs.  Quantification of 23 
densitometry values revealed that V37E-GFP and A88V-GFP protein levels were ~35% and 24 
~50% lower, respectively, compared to the relative expression of Cx30-GFP (**P<0.01) (Fig. 25 
1B, C).  In contrast, the non-syndromic hearing loss-linked T5M and Vohwinkel syndrome-26 
linked G59R mutants exhibited expression levels similar to that of Cx30-GFP. 27 
To compare the localization profiles of the mutant forms of Cx30, we examined GFP-28 
tagged Cx30 mutants (Fig. 2A) and untagged Cx30 mutants (Fig. 2B, C) in REKs.  Consistent 29 
with previous reports, the T5M mutant formed gap junction-like plaques at the cell surface 30 
similar to wt Cx30, while the V37E and A88V Clouston syndrome-linked mutants appeared to 31 
remain in intracellular compartments (Common et al., 2002; Essenfelder et al., 2004) (Fig. 2A, 1 
B).  Immunolabeling for the ER-resident protein disulfide isomerase (PDI) revealed that the 2 
Clouston syndrome/KID syndrome-linked V37E mutant was retained in the ER (Fig. 2A).  A88V 3 
mutant-expressing cells appeared to be entering a cell death pathway as they exhibited small and 4 
fragmented nuclei, and since they lacked PDI staining, it remains unclear whether a significant 5 
population of this mutant resides in the ER.  The novel Vohwinkel syndrome-linked G59R 6 
mutant (Nemoto-Hasebe et al., 2009) also showed an intracellular localization profile (Fig. 2A, 7 
B), and immunolabeling for Golgi matrix protein 130 (GM130) revealed its localization largely 8 
in the Golgi apparatus (Fig. 2C).  Interestingly, while we have never observed V37E plaques at 9 
the interface between apposing cells, a population of the G59R and A88V mutants successfully 10 
trafficked to the cell surface to form gap-junction-like plaques (Fig. 2A, B, arrows).  Cx30 and 11 
Cx30 mutants all similarly localized within the cell regardless of the presence or absence of the 12 
GFP tag (Fig. 2A-C). 13 
 14 
V37E and A88V Cx30 mutants affect endogenous Cx43 localization in REKs and 15 
ectopic Cx43 localization in HeLa cells – To determine whether the presence of the Cx30 16 
mutants affected endogenous Cx43 localization, REKs were engineered to express Cx30-GFP or 17 
the equivalent GFP-tagged mutants.  For the T5M and G59R mutants, Cx43 frequently co-18 
localized with Cx30 mutants at cell-cell interfaces, whereas Cx43-based gap junctions appeared 19 
less frequently between cells expressing the V37E and A88V mutants (Fig. 3A).  The total 20 
protein levels of Cx43, however, remained unchanged (Fig. 3B, C).  Total Cx43 levels were only 21 
slightly decreased in T5M mutant-expressing cells compared to those expressing Cx30 22 
(*P<0.05).  In agreement with these findings, HeLa cells that were engineered to express Cx30 23 
mutants with Cx43-RFP showed similar localization profiles (Fig. S1). Both wt Cx30 and T5M 24 
frequently co-localized in plaque-like structures, whereas cells expressing V37E and A88V 25 
mutants exhibited less plaque formation and Cx43 was more evident in intracellular 26 
compartments. The G59R mutant had reduced plaque-like structures but it did not prevent Cx43 27 
from trafficking to the cell surface (Fig. S1). 28 
 29 
V37E and G59R skin disease-linked Cx30 mutants exhibit loss of gap junction 30 
function in HeLa cells – Since the T5M mutant and a population of the G59R mutant formed 31 
punctate gap junction-like structures at the cell surface in REKs, we hypothesized that these 1 
mutants may form functional gap junctions.  Mutant-expressing GJIC-deficient HeLa cells were 2 
microinjected with Alexa 350 to assess whether any of the mutants restored GJIC.  As expected, 3 
Cx30 gap junction channels readily facilitated dye transfer (***P<0.001), while untransfected 4 
(Untr) and free GFP-expressing cells showed no significant dye transfer to surrounding cells 5 
(Fig. 4A, B).  Interestingly, the T5M mutant exhibited dye transfer in ~90% (***P<0.001) of 6 
cells injected (Fig. 4A, B), indicating that this mutant was functional.  No dye transfer was 7 
observed in microinjected HeLa cells expressing the V37E and G59R mutants (Fig. 4A, B).  8 
A88V-expressing cells were not included in these functional studies, as they could not be 9 
microinjected due to their porous cell membranes caused by cell death (see Fig. 5C). 10 
 11 
V37E and A88V Cx30 mutants reduce coupling in Cx43-positive REKs – Since the 12 
Cx30 mutants had the ability to affect Cx43 localization, we wanted to determine whether Cx30 13 
mutants affected GJIC in Cx43-rich REKs. GFP-tagged mutant-expressing REKs were 14 
microinjected with Alexa 350 in a region where cell clusters were expressing GFP, and the 15 
incidence of dye transfer was recorded.  Untransfected REKs exhibited 100% dye transfer, and 16 
no significant differences in dye transfer were observed in REKs expressing GFP, Cx30, or the 17 
T5M and G59R mutants (Fig. 4C, D).  In contrast, cell pairs or clusters expressing the V37E and 18 
A88V mutants exhibited significantly decreased Cx43-mediated dye transfer (**P<0.01) (Fig. 19 
4C, D). 20 
 21 
The V37E and G59R mutants do not form functional cell surface hemichannels – 22 
The ability of each Cx30 mutant to form functional hemichannels was investigated by observing 23 
the incidence of propidium iodide (PI) dye uptake in Cx30 or mutant expressing HeLa cells 24 
under normal extracellular solution (ECS) and Ca2+/Mg2+ divalent cation free ECS (DCF-ECS) 25 
conditions, which induces hemichannels to open (Lai et al., 2006; Stout et al., 2002). Under ECS 26 
conditions, any putative Cx30, T5M, V37E or G59R mutant hemichannels would remain closed 27 
and as expected, no dye uptake was observed (Fig. 5A).  Under DCF-ECS conditions, ~90% of 28 
isolated T5M-expressing cells exhibited dye uptake, closely resembling the ~95% incidence 29 
observed for cells expressing Cx30, both of which were significantly higher than that observed 30 
under control ECS conditions (***P<0.001) (Fig. 5A, B).  In contrast, the V37E and G59R 31 
mutant expressing cells did not exhibit any dye uptake in DCF-ECS conditions.  The loss of cell 1 
membrane integrity was evident in A88V mutant expressing cells since ~75% of the cells 2 
exhibited uptake of the hemichannel impermeable dye dextran-rhodamine (MW, 10 kDa) in 3 
normal ECS conditions.  In contrast, wt Cx30 expressing cells did not uptake dextran-rhodamine 4 
in ECS (Fig. 5C).  Collectively, these studies indicated that V37E and G59R mutants were loss-5 
of-function mutants while the T5M mutant showed similar functional channel properties to 6 
Cx30.  The A88V mutant caused membrane disruption and cell death 24 hours after expression, 7 
therefore hemichannel status could not be assessed. 8 
 9 
V37E and A88V mutants induce apoptosis by distinct mechanisms – The ectopic 10 
expression of the V37E and A88V mutants induced some degree of cell death in REKs as early 11 
as 18 hours post-expression, with the majority of A88V-expressing cells dying within 48 hours 12 
(data not shown).  To determine the mechanism of cell death induced by these mutants, control 13 
and mutant-expressing REKs were immunolabeled with anti-cleaved caspase-3, a marker of the 14 
committed stage of apoptosis (Saraste and Pulkki, 2000).  Interestingly, some V37E- and A88V-15 
expressing REKs expressed cleaved caspase-3, indicating that these cells were undergoing 16 
apoptosis (Fig. S2).  To further validate and quantify this finding, TUNEL assays representing 17 
the degradation stage of apoptosis (Saraste and Pulkki, 2000) were performed on Cx30- and 18 
mutant-expressing REKs.  V37E and A88V Cx30 mutants significantly induced apoptosis, as 19 
~70% and ~80% of GFP-expressing cells, respectively, were ApopTag positive (***P<0.001) 20 
compared to GFP only REKs, of which only ~2% were ApopTag positive (Fig. 6A, B).  Untr 21 
cells treated with staurosporine (Stauro) for 24 hours served as a positive control for the assay, as 22 
~90% of total cells were apoptotic in comparison to Untr controls (***P<0.001, Fig.  6C).   23 
Since some of the mutants localized to the ER we wanted to determine whether apoptosis 24 
was triggered by an ER stress-mediated unfolded protein response (UPR).  Western blot analyses 25 
of REK cell lysates were performed to detect changes in levels of markers involved in different 26 
stages and pathways of the UPR.  REKs treated with tunicamycin (Tm), an ER stress inducer that 27 
blocks N-glycosylation of proteins (de Freitas Junior et al., 2011), served as positive controls for 28 
UPR markers.  When compared to GFP-expressing cells, GRP78 expression was not elevated in 29 
any mutant-expressing cells (Fig. S3A).  The activating transcription factor 4 (ATF4) was mildly 30 
up-regulated in cells expressing only the V37E mutant (***P<0.001) (Fig. S3B).  Finally, the 31 
C/EBP homologous protein (CHOP) was not elevated in any mutant expressing cells when 1 
compared to GFP expressing control cells and only significantly increased in tunicamycin (Tm)-2 
treated cells (Fig. S3C).  3 
To determine whether the Cx30 V37E mutant activates the IRE1 arm of the UPR we 4 
performed an X-box binding protein 1 (XBP1) splicing assay (Calfon et al., 2002; Williams and 5 
Lipkin, 2006).  In response to unfolded proteins, IRE1 directly splices a small intron from XBP1 6 
mRNA (Ron and Walter, 2007) containing a single PstI restriction site (Fig. S3D-G).  Agarose 7 
gel analysis of XBP1 cDNA confirmed the presence of the unspliced product in Untr controls as 8 
determined by the doublet band at ~300 bp (XBP1u) and low expression of the spliced 575 bp 9 
band (XBP1s) after PstI digestion (Fig. S3F).  The Tm control had elevated levels of undigested 10 
cDNA (575 bp) and a complete loss of the unspliced fragments (XBP1u), suggesting the vast 11 
majority of XBP1 mRNA was spliced.  In comparison to the untransfected control, Cx30 and the 12 
T5M, V37E, G59R and A88V mutants displayed no discernible differences in XBP1 splicing 13 
(Fig. S3F).  Detailed images of the higher bands (Fig. S3F) revealed a slight increase in XBP1s 14 
(575 bp) in comparison to XBP1u (601 bp) for transfected cells, but this was most likely a result 15 
of protein over-expression.  The ratio of the 575 bp band to the ~300 bp doublet band showed 16 
that only the Tm control significantly induced splicing of XBP1 mRNA (Fig. S3G, N = 6, 17 
***P<0.001), suggesting that the V37E mutant did not induce an IRE1-mediated UPR. 18 
 19 
V37E and A88V mutants may exhibit dominant-negative and transdominant effects 20 
on wt Cx30 and Cx26 when co-expressed in REKs – To determine whether skin disease-linked 21 
Cx30 mutants localized to intracellular compartments could be rescued to the cell surface, REKs 22 
were engineered to express red fluorescent protein (RFP)-tagged Cx30 (Cx30-RFP) or Cx26-23 
RFP simultaneously with GFP-tagged Cx30 mutants.  Alone, Cx30-RFP formed gap junctions 24 
(Fig. 7), which also facilitated the transfer of Alexa 350 in HeLa cells and REKs (data not 25 
shown).  Cx30-GFP and T5M-GFP showed distinct co-localization with Cx30-RFP, with limited 26 
intracellular localization, whereas wt Cx30 did not appear to rescue the V37E mutant to the cell 27 
surface (Fig. 7).  Although the G59R and A88V mutants showed some co-localization with wt 28 
Cx30 at the cell surface, the majority of these mutants were localized in intracellular 29 
compartments indicating that co-expression with wt Cx30 was not enough to fully rescue the 30 
trafficking of Cx30 mutants to the cell surface. (Fig. 7).  Notably, the V37E and A88V mutants 31 
may exhibit partial dominant-negative effects on wt Cx30, as a large population of Cx30-RFP 1 
was retained inside the cell as compared to situations where Cx30-RFP was expressed alone 2 
(Fig. 7).  In particular, the A88V mutant and wt Cx30 exhibited overlapping co-localization in a 3 
distinct subcellular compartment.  We also observed similar results in HeLa cells, whereby the 4 
V37E, G59R and A88V mutants all exhibited small amounts of co-localization with wt Cx30 at 5 
the cell surface, but the vast majority of mutant protein was localized intracellularly (Fig. S4).  6 
Alone, Cx26-RFP formed gap junctions in REKs (Fig. 8).  Cx30-GFP, T5M-GFP and G59R-7 
GFP also showed co-localization with Cx26-RFP, however the V37E, A88V and the majority of 8 
the G59R mutant remained within intracellular compartments indicating that wt Cx26 did not 9 
rescue the trafficking of these mutants (Fig. 8).  However, the V37E and A88V mutants also may 10 
exhibit transdominant effects on Cx26, as the majority of Cx26-RFP was retained inside the cell 11 
compared to when Cx26-RFP was expressed alone (Fig. 8).  Again, similar results were also 12 
obtained in HeLa cells engineered to express Cx30 and Cx30 mutants with Cx26-RFP. Cx30 and 13 
T5M showed strong co-localization at gap junction plaques (Fig. S4).  The G59R mutant also co-14 
localized strongly with Cx26-RFP at gap junction plaques, but a population of the mutant 15 
remained within intracellular compartments. The V37E mutant appeared to have transdominant 16 
effects on Cx26-RFP by reducing the evidence of Cx26-RFP found in plaques, whereas a portion 17 
of A88V could traffic to the cell surface with Cx26-RFP (Fig. S4).  18 
 19 
DISCUSSION 20 
 In the present study, we first determined that the T5M mutant linked to non-syndromic 21 
hearing loss exhibited similar properties to wt Cx30, as it formed functional gap junctions and 22 
hemichannels.  Skin disease-linked mutants exhibited impaired gap junction formation and 23 
function.  In particular, the V37E mutant linked to KID syndrome was retained in the ER and 24 
triggered apoptosis, leading to the hypothesis that this was occurring via the UPR. However, 25 
only the UPR marker ATF4 was modestly elevated in cells that expressed this mutant with all 26 
other indices of UPR remaining unchanged. This suggests that cell death was likely triggered by 27 
an UPR independent mechanism.  In contrast, the G59R mutant associated with Vohwinkel and 28 
Bart-Pumphrey syndromes was primarily retained in the Golgi apparatus, and did not induce cell 29 
death.  The A88V mutant linked to Clouston syndrome remained primarily in intracellular 30 
compartments, but did have the capability of reaching the cell surface. Nevertheless, it potently 31 
induced apoptosis possibly through mechanisms that could include leaky hemichannels that may 1 
occur within an intracellular compartment or at the cell surface.  Finally, we determined that skin 2 
disease-linked mutants retained in intracellular compartments were not effectively rescued to the 3 
cell surface by co-expressed Cx43, Cx30 or Cx26, and the V37E and A88V mutants exhibited 4 
dominant-negative and transdominant effects on the trafficking of these connexins to the cell 5 
surface.  Thus, we clearly demonstrated the overall complexity of connexin-linked diseases, as 6 
each Cx30 mutant exhibited markedly different characteristics and transdominant properties 7 
within cells. These findings also show that the disease phenotype correlates with the severity of 8 
the mutant on cellular health and overall GJIC. 9 
In order to evaluate the link between Cx30 mutants and disease, we used spontaneously 10 
immortalized, newborn REKs, which have previously been reported to express messenger RNA 11 
(mRNA) for 9 connexins, including Cx30 (Maher et al., 2005), and are phenotypically similar to 12 
basal keratinocytes given their ability to differentiate and stratify (Langlois et al., 2007; Maher et 13 
al., 2005; Thomas et al., 2007).  At the protein level, REKs abundantly express Cx43, and only 14 
express Cx26 upon differentiation (Maher et al., 2005). The fact that REKs did not express 15 
detectable levels of Cx30 allowed us to express and track both GFP-tagged and untagged 16 
versions of Cx30 and mutants.  Similar localization profiles and function were observed for all 17 
GFP-tagged and untagged Cx30 and Cx30 mutants, strongly suggesting that the presence of GFP 18 
on the C-terminal tail did not affect the properties of Cx30, similar to what has been reported for 19 
Cx26 (Marziano et al., 2003) and Cx43 (Jordan et al., 1999).   20 
 21 
The non-syndromic hearing loss-linked T5M mutant.  The T5M mutant is one of only two 22 
Cx30 mutants linked specifically to non-syndromic hearing loss (Grifa et al., 1999; Wang et al., 23 
2011).  Consistent with our results, the T5M mutant was previously found to form gap junctions 24 
(Common et al., 2002), however, its functional capacity remains controversial.  In vitro 25 
electrophysiological studies previously showed that the T5M amino acid substitution drastically 26 
reduced electrical coupling between Xenopus laevis oocytes (Grifa et al., 1999), while other 27 
reports showed restrictions in the transjunctional molecules that can pass through T5M channels 28 
(Common et al., 2002; Schutz et al., 2010; Zhang et al., 2005).  In our study, we found that both 29 
T5M-based hemichannels and gap junction channels were functional to the passage of sizable 30 
molecules (e.g. prodium iodide, Alexa 350) in mammalian cells, raising the question as to why 1 
this mutant causes hearing loss.   2 
The answer may be linked to subtle changes in the N-terminal domain of Cx30 where the 3 
‘threonine’ to ‘methionine’ substitution occurs.  Cx30 shares 76% sequence homology with 4 
Cx26 (Grifa et al., 1999), and while the crystal structure of Cx30 has not yet been resolved, the 5 
crystal structure of Cx26 has elucidated that the amino terminal tail lines the gap junction 6 
channel pore, creating a funnel that restricts channel selectivity based on molecular size, 7 
flexibility, charge and charge distribution (Harris, 2007; Kwon et al., 2011; Maeda et al., 2009).  8 
In the non-sensory cells of the inner ear, Cx26 and Cx30 intermix to form heteromeric and 9 
heterotypic channels (Ahmad et al., 2003; Forge et al., 2003; Marziano et al., 2003; Yum et al., 10 
2007), and are suggested to form functional hemichannels (Gossman and Zhao, 2008; Zhao et 11 
al., 2005).  Through extrapolation, a mutation of the highly conserved hydrophilic T5 Cx30 12 
amino acid (Grifa et al., 1999) may alter the permeability properties of both homotypic Cx30 and 13 
heterotypic Cx26/Cx30 channels.  Another possibility may be how the T5M mutant affects 14 
Cx26, since the role of Cx30 in hearing remains controversial (Boulay et al., 2013; Miwa et al., 15 
2013; Teubner et al., 2003) and increasing evidence suggests that Cx26 and Cx30 are co-16 
regulated (Boulay et al., 2013).  Expression levels of Cx26 were dramatically reduced in Cx30 17 
knock-out (Boulay et al., 2013) and in Cx30 T5M knock-in mice that also exhibited decreased 18 
levels of Cx30 (Schutz et al., 2010).  Importantly, in the inner ear, this mutant may be affecting 19 
Cx26 levels, potentially reducing the frequency of heteromeric and heterotypic channel 20 
formation necessary for K+ buffering.  In addition, Cx30 has been reported to be involved in 21 
glucose uptake and metabolic coupling between mouse cochlear cells (Chang et al., 2008).  22 
Therefore, the T5M mutation, although able to pass ions and molecular dyes, may reduce, but 23 
not inhibit, the permeability of metabolites such as glucose between supporting cells in the 24 
avascular sensory epithelium.  However further investigation is necessary to clearly understand 25 
how the T5M mutation has such effects.   26 
Our finding that T5M gap junction channels and hemichannels are functional agrees in 27 
part with other findings that suggest ionic permeability is not affected by this amino acid 28 
substitution (Schutz et al., 2010; Zhang et al., 2005).  However, larger molecules such as 29 
propidium iodide (PI) (Zhang et al., 2005), inositol trisphosphate (IP3) and calcein (Schutz et al., 30 
2010) have been reported to have reduced permeability.  The intercellular transfer of calcein and 31 
IP3 was observed between cells obtained from organotypic cochlear cultures from Cx30T5M/T5M 1 
mice where Cx26 is also known to be co-expressed.  Thus, the presumed heteromeric 2 
conformation of Cx30T5M/Cx26 channels may have an overriding effect on channel 3 
permeability/selectivity in comparison to homomeric T5M channels. However, the ability for the 4 
T5M mutant to uptake PI and transfer Alexa 350 in our study contrasts to that by (Zhang et al., 5 
2005) and (Common et al., 2002), respectively.  We can only speculate on this issue and suggest 6 
it may be due to differences in linker sequences joining the T5M mutant to GFP or differences in 7 
species sequences.  Nevertheless, the fact that the T5M mutant is functional has been rigorously 8 
established suggesting that disease is likely linked to more subtle changes in channel regulation 9 
or changes in the structure of the amino terminus.  10 
 11 
The loss-of-function V37E mutant linked to Clouston and KID syndromes.  Although 12 
previously considered to be linked distinctly to Clouston syndrome (Common et al., 2002; Smith 13 
et al., 2002), the V37E mutant has now also been implicated in KID syndrome (Jan et al., 2004).  14 
Other than the fact that the V37E mutant was retained in an unknown intracellular compartment 15 
(Common et al., 2002), little was known about this mutant.  Here, we conclusively show that the 16 
V37E mutant is retained within the ER where it is surveyed by molecular machinery as part of 17 
cellular quality control (Kleizen and Braakman, 2004).  Furthermore, this loss-of-gap junction 18 
channel and -hemichannel function mutant acted in a (trans)dominant-negative fashion on co-19 
expressed Cx43, Cx26 and Cx30 and significantly induced apoptosis in REKs.   20 
The V37E mutant is positioned in the 1st transmembrane domain of Cx30.  According to 21 
the crystal structure of Cx26, the 1st transmembrane domain is the major pore-lining helix 22 
involved in prominent intra-connexin interactions with all other transmembrane domains, which 23 
stabilizes the basic structure of the connexin subunit (Maeda et al., 2009).  In addition, the V37 24 
amino acid is located in a motif (VVAA) conserved between Cx26 and Cx30 (Maeda et al., 25 
2009; Smith et al., 2002), and as demonstrated by the V37I Cx26 mutant, mutations within this 26 
particular motif reduce hexamer formation and channel function (Jara et al., 2012).  Importantly, 27 
the V37E Cx30 mutation involves a more unique and critical substitution of a hydrophobic 28 
‘valine’ with an acidic ‘glutamic acid’ residue, which we propose alters critical intra-connexin 29 
interactions and Cx30 stability, resulting in improper folding and protein accumulation in the 30 
ER.  In addition, various Cx26 mutants linked to Vohwinkel syndrome and PPK have been 31 
reported to exhibit dominant-negative and transdominant effects on other connexins, including 1 
Cx30 and Cx43 (Forge et al., 2003; Marziano et al., 2003; Rouan et al., 2001).  While V37E 2 
Cx30 may exhibit these effects on co-expressed wt Cx30, Cx26 and Cx43, it is also possible that 3 
V37E-mutant expressing cells undergoing apoptosis are internalizing these connexins, as has 4 
been reported for Cx43 (Kalvelyte et al., 2003).   5 
When the V37E mutant was expressed in keratinocytes, it induced apoptotic cell death 6 
that we hypothesized might occur through the UPR. The UPR is a protective cellular mechanism 7 
regulated by luminal ER chaperone GRP78 (Malhotra and Kaufman, 2007), and is involved in 8 
normal keratinocyte differentiation (Sugiura et al., 2009) as well as normal lens development 9 
(Alapure et al., 2012).  Of note, mutations in Cx31 and Cx50 linked to erythrokeratoderma 10 
variabilis (EKV) and cataracts, respectively, induce an abnormal ER stress-mediated UPR 11 
(Alapure et al., 2012; Tattersall et al., 2009) and result in extensive cell death (Di et al., 2002; He 12 
et al., 2005).  While the expression of the V37E Cx30 mutant did not induce the up-regulation of 13 
GRP78, which may occur upon the activation of the activating transcription factor 6 (ATF6) 14 
pathway (Berridge, 2002), the V37E mutant only moderately induced the expression of ATF4.  15 
ATF4 activates cell death-initiating caspases, including caspase 3, through the mitochondrial-16 
dependent intrinsic cell death pathway (Galehdar et al., 2010; Groenendyk and Michalak, 2005; 17 
Malhotra and Kaufman, 2007).  In contrast, the ER-stress induced splicing of XBP1 via IRE1 18 
was negative in V37E mutant expressing cells, suggesting that the mechanism of cell death may 19 
in fact be independent of the UPR.  This was somewhat surprising since the V37E mutant clearly 20 
accumulates in the ER and initiates apoptosis. However, evidence exists which suggests that 21 
misfolded secretory proteins, such as an α1-antitrypsin Z mutant, can accumulate in the ER, 22 
induce ER vesiculation and activate caspase-dependent pathways without activating the UPR 23 
(Hidvegi et al., 2005). In addition, NFκB activation and calcium release from the ER via an 24 
alternative ER overload response (EOR) pathway have also been demonstrated to be distinct 25 
from the UPR (Pahl et al., 1996). Various stresses such as changes in ER calcium (Subramanian 26 
and Meyer, 1997) can similarly alter ER structure but the functional relevance of these 27 
alterations is unclear. Whether the V37E mutant is causing cell death through these alternative 28 
UPR-independent pathways remains to be determined, but the short time frame and rapid 29 
activation of apoptosis makes further dissection of the mechanisms involved difficult to 30 
ascertain.   31 
The loss-of-function G59R mutant linked to Vohwinkel/Bart-Pumphrey syndromes.  Here, 1 
a previously uncharacterized loss-of-function Cx30 G59R mutant was found to occasionally 2 
form gap junction plaques, but was mainly localized to the Golgi apparatus.  This is consistent 3 
with findings for Vohwinkel syndrome-linked G59A and D66H Cx26 mutants (Bakirtzis et al., 4 
2003; Marziano et al., 2003; Thomas et al., 2004), suggesting that mutations in the 1st 5 
extracellular domain of Cx30 and Cx26 may lead to similar disease phenotypes.  Supporting the 6 
essential role of the 1st extracellular loop, the N45K Cx26 mutation located in this domain causes 7 
Bart-Pumphrey syndrome (Richard et al., 2004).  The evolutionarily conserved 1st extracellular 8 
loop of Cx26 (and by extension Cx30) has been suggested to play a role in voltage gating (Tang 9 
et al., 2009; Verselis et al., 2009), and more importantly, inter-connexin and inter-connexon 10 
interactions (Maeda et al., 2009).  Therefore, the Cx30 G59R mutant may result in defective 11 
connexin oligomerization, which occurs primarily in the ER and Golgi apparatus for several 12 
connexins including Cx32,  Cx26, Cx43 and Cx46 (Das Sarma et al., 2002; Evans et al., 1999; 13 
Koval et al., 1997; Musil and Goodenough, 1993).  Reduced channel function at the cell surface 14 
may also indicate defective hemichannel docking, highlighting the importance of this domain in 15 
channel formation and function linked to hearing loss and skin diseases. 16 
 17 
The A88V mutant linked to Clouston syndrome.  The A88V mutant is one of four mutations 18 
linked to Clouston syndrome.  Previous studies localized the A88V mutant to intracellular 19 
compartments, which could be partially rescued to the cell surface when co-expressed with wt 20 
Cx30 (Common et al., 2002; Essenfelder et al., 2004).  The A88V mutant was also found to 21 
exhibit abnormal hemichannel activity associated with ATP release and subsequent cell death 22 
(Essenfelder et al., 2004).  We extended these studies by demonstrating that a population of the 23 
A88V mutant also formed gap junction-like structures, and negatively affected Cx43-based gap 24 
junction coupling and the trafficking of both wt Cx26 and Cx30.  These dominant-negative and 25 
transdominant effects may also be cumulated with the fact that the A88V mutant significantly 26 
induced apoptosis in REKs, similar to our suggestion for the V37E mutant.   27 
Clearly, the A88 amino acid is critical for Cx30 hemichannel and channel function.  Cx30 28 
forms voltage-gated hemichannels (Valiunas and Weingart, 2000), which are normally closed 29 
under physiological conditions and open in response to low extracellular concentrations of Ca2+ 30 
and Mg2+ (De Vuyst et al., 2007; Tong et al., 2007; Verselis and Srinivas, 2008).  Importantly, 31 
leaky hemichannels resulting in cell death have been reported for a number of other connexin 1 
mutations (Gerido et al., 2007; Lee et al., 2009; Mese et al., 2011; Stong et al., 2006), and also 2 
for the A88V Cx26 mutation which is linked to KID syndrome (Mhaske et al., 2013).  The 3 
crystal structure of Cx26 suggests that part of the 2nd transmembrane domain also lines the 4 
channel pore and is involved in intra-connexin interactions with other domains including the 5 
amino terminus that dictate specific protein conformation (Kwon et al., 2011; Maeda et al., 6 
2009).  By analogy, it is possible that the A88V Cx30 mutation affects protein folding and 7 
stability, and alters important interactions, moving the amino terminal domain away from the 8 
cytoplasmic entrance of the pore (Kwon et al., 2011; Maeda et al., 2009) to favour abnormal 9 
hemichannel activity.  Therefore, we propose that leaky A88V Cx30 hemichannels contribute to 10 
induced apoptosis in REKs. Since Cx30 likely oligomerizes early in the secretory pathway, leaky 11 
A88V hemichannels (or connexons) would disrupt the calcium gradient in the ER and other 12 
compartments possibly triggering a rapid cell death response.  13 
 In conclusion, the present study characterized four Cx30 mutations linked to skin disease 14 
(A88V), hearing loss (T5M) and combinations of both (V37E and G59R).  Each mutation results 15 
in disease manifestations through distinct mechanisms ranging from a mutant that exhibits wild 16 
type Cx30 characteristics (T5M) to mutants that induce apoptosis through possible constitutive 17 
and premature activation of hemichannels, or through ER signalling mechanisms that are UPR-18 
independent (A88V, V37E). Moreover, the loss-of-function G59R mutant causes yet another 19 
skin disease phenotype manifesting as a combination of Vohwinkel and Bart-Pumphrey 20 
syndromes.  While all of these Cx30 autosomal dominant gene mutations cause syndromic and 21 
non-syndromic disease by different mechanisms, future studies will need to determine the key 22 
role of co-regulated connexins in the cochlea and epidermis.   23 
 24 
MATERIALS AND METHODS 25 
Generation of cDNA constructs  26 
Mouse Cx30 complementary DNA (cDNA) encoded within the pBluescript vector, 27 
kindly provided by Dr. C. C. Naus (UBC, Vancouver, BC), was cloned into a pEGFP expression 28 
vector using XhoI and NotI restriction enzymes. This combination of restriction enzymes 29 
removes the enhanced GFP (eGFP) cDNA from the vector as described by Thomas et al. (2004).  30 
Cx30 mutants were constructed using the QuikChange site-directed mutagenesis kit (Stratagene, 31 
La Jolla, CA) as per the manufacturer’s instructions.  The following primer pairs were used to 1 
create the Cx30 mutations.  The nucleotide change is underlined in each case:  2 
T5M: sense, 5’-GCACGATGGACTGGGGGATGCTGCACACCGTCATCGG-3’; antisense, 5’-3 
CCGATGACGGTGTGCAGCATCCCCCAGTCCATCGTGC-3’;  4 
V37E: sense, 5’-CCGAGTCATGATCCTAGAGGTGGCTGCCCAG-3’; antisense, 5’-5 
CTGGGCAGCCACCTCTAGGATCATGACTCGG-3’;  6 
A88V: sense, 5’-CTTTGTGTCTACCCCAGTCCTGTTGGTGGCCATGC-3’; antisense, 5’-7 
GCATGGCCACCAACAGGACTGGGGTAGACACAAAG-3’.   8 
The G59R mutant was purchased from Norclone Biotech Laboratories (London, ON).  All 9 
mutations were validated by sequencing, indicating the presence of the mutation and ensuring 10 
that no other mutations were introduced.   11 
To create GFP-tagged constructs and Cx30-RFP, polymerase chain reaction (PCR) was 12 
performed to introduce XhoI and EcoRI restriction sites to the 5’ and 3’ ends of the Cx30 and 13 
Cx30 mutant sequences; respectively, removing the stop codon and allowing for the expression 14 
of GFP.  Following digestion with XhoI and EcoRI restriction enzymes, the PCR products were 15 
cloned into the pEGFP-N1 (Clontech, Palo Alto, CA) and pTagRFP-N (Evrogen, Cedarlane as 16 
distributor, Burlington, ON) vectors to produce GFP-tagged constructs and Cx30-RFP, 17 
respectively.  Cx43-mRFP was kindly provided by Dr. Guido Gaietta (University of California, 18 
San Diego, CA) as described before (Gong et al., 2007).  For Cx26-RFP, Cx26 cDNA was 19 
digested from Cx26-YFP (Laird et al., 2001) by using XhoI and EcoRI restriction enzymes and 20 
directly subcloned into pTagRFP-N vector as mentioned above. All constructs were sequenced 21 
for verification. 22 
 23 
Cell Culture and Transient Transfections 24 
 GJIC-competent REKs, kindly provided by Dr. Vincent C. Hascall (Cleveland Clinic, 25 
Cleveland, OH), and communication-deficient HeLa cells (ATCC, Manassas, VA) were cultured 26 
in high glucose Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal 27 
bovine serum, 100 U/mL penicillin, 100 µg/mL streptomycin and 2 mM L-glutamine 28 
(Invitrogen, Burlington, ON), in a humidified incubator maintained at 37°C with 5% CO2 as 29 
previously described (Maher et al., 2005).  Cells were passed once they reached 80-100% 30 
confluency using 0.25% trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA) (Invitrogen), 31 
and were cultured in 35 mm or 60 mm plastic tissue culture dishes for all experimental 1 
procedures.  Prior to transfection, all cells were grown to 65-80% confluency, and those destined 2 
for immunolabeling or terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) 3 
assays were also grown on glass coverslips.  Cells were transfected with 2-6 µg of DNA using 4 
Lipofectamine 2000 (Invitrogen) in the presence of low serum OptiMEM medium (Invitrogen) 5 
as previously described (Penuela et al., 2007) or using the JetPRIME-mediated transfection kit 6 
(VWR International, Mississauga, ON) according to the manufacturer’s instructions.  As 7 
controls, untransfected cells were exposed to transfection reagents and the appropriate media 8 
without the addition of any DNA.  As a second control, a population of cells was also transfected 9 
with a vector encoding free GFP.  Co-transfections were performed using the Polyplus 10 
JetPRIME transfection method by mixing 1µg of Cx30- or Cx26-RFP and 1 µg of each GFP-11 
tagged Cx30 mutant.  All transfections were terminated after 24 hours.  Positive controls for the 12 
induction of ER stress or apoptosis included cells plated in parallel, treated for 24 hours with 2 13 
µg/mL tunicamycin or 0.5 µg/mL staurosporine, respectively (both from Sigma Aldrich, St 14 
Louis, MO). 15 
 16 
Immunocytochemistry   17 
Cells grown in monolayer on glass coverslips were fixed with 10% neutral buffered 18 
formalin (NBF) (EMD Millipore, Billerica, MA) for 25 minutes at room temperature.  In a 19 
humidified chamber, fixed cells were blocked for 30-45 minutes at room temperature in 20 
phosphate buffered saline (PBS) containing 2% bovine serum albumin (BSA) (Santa Cruz 21 
Biotechnology, Dallas, TX), to prevent non-specific antibody binding, and 0.1% Triton X-100 22 
(Sigma Aldrich) for permeabilization.  Endogenous or ectopic connexin expression and 23 
localization was detected by labeling with rabbit anti-Cx43 (1:500, Sigma Aldrich) or anti-Cx30 24 
(1:500, Invitrogen) antibodies for 1 hour.  In some cases, cells were labeled with mouse anti-PDI 25 
(1:500, Enzo Life Sciences, Farmingdale, NY) to denote the position of the ER, mouse anti-26 
GM130 (1:500, BD Transduction Laboratories, Mississauga, ON) to demarcate the Golgi 27 
apparatus or rabbit anti-cleaved caspase-3 (1:1000, Cell Signaling Technology, Danvers, MA) to 28 
denote cells undergoing apoptosis.  Cells were then incubated with secondary AlexaFluor555 or 29 
AlexaFluor488 conjugated antibodies (1:500, Invitrogen) for 45-60 minutes, and stained for 5-10 30 
minutes with Hoescht 33342 (1:1000, Invitrogen) to denote the nuclei.  Cells were mounted on 31 
glass microscope slides.  Cells co-transfected with Cx30- or Cx26-RFP and GFP-tagged Cx30 1 
mutants were not immunolabeled, but were stained with Hoescht 33342 and mounted as 2 
described above.  All slides were stored at 4°C with minimal exposure to light.  Slides were 3 
imaged using a Zeiss LSM 510 confocal microscope (Thornwood, NY) equipped with a 63X 4 
lens as previously outlined by Thomas et al. (2007). 5 
 6 
Microinjection Assays  7 
In order to test Cx30 and mutant gap junction function, REKs and HeLa cells ectopically 8 
expressing Cx30 or mutants were microinjected with 10 mM Alexa Fluor 350 hydrazide 9 
(Invitrogen) using an automated Eppendorf FemtoJet microinjection system (Mississauga, ON) 10 
as previously described (Huang et al., 2013).  For each biological replicate of GFP-, Cx30-, 11 
T5M-, V37E- and G59R-expressing cells, ~15-20 cells were microinjected and the incidence of 12 
dye transfer to surrounding cells was recorded.  Images were acquired using a Leica DM IRE2 13 
inverted epifluorescent microscope (Richmond Hill, ON), equipped with a Hamamatsu digital 14 
camera (Bridgewater, NJ) and OpenLab 5.5.3 Imaging Software (Lexington, MA).  HeLa cells 15 
expressing the A88V mutant could not be microinjected due to the fact that cells were already 16 
undergoing cell death and had a permeable cell membrane, however in the case of REKs, 5-10 17 
cells were microinjected in each replicate.  REKs and HeLa cells were microinjected and 18 
processed in the same manner to ensure that cells were well coupled and connexin-deficient, 19 
respectively.  A one-way ANOVA was performed on the averages of 3 biological replicates, and 20 
values represent the mean percent incidence of dye transfer ± s.e.m.  21 
 22 
Dye Uptake Hemichannel Assays 23 
 To assess Cx30 and mutant hemichannel function, dye uptake assays were performed as 24 
previously described by Tong et al. (2007) with some modifications.  Briefly, HeLa cells plated 25 
as single isolated cells were transfected with 1.5 µg of DNA as described above using 26 
Lipofectamine 2000.  Normal extracellular solution (ECS, in mM: 142 NaCl, 5.4 KCl, 1.4 27 
MgCl2, 2 CaCl2, 10 HEPES, 25 D-Glucose, osmolarity 298 mOsm, pH adjusted to 7.35 with 28 
NaOH) and divalent cation free-ECS (DCF-ECS, same recipe as for ECS except Ca2+ and Mg2+ 29 
were replaced with 2 mM EGTA) were added to cells with 0.15 mM propidium iodide (PI, MW 30 
668.4 Da, Invitrogen).  Groups of single isolated Cx30- or mutant-expressing cells were analyzed 31 
for their ability to uptake PI under physiological (ECS) and no Ca2+ or Mg2+ (DCF-ECS) 1 
conditions.  Images were taken under a 20X lens using the Leica microscope and OpenLab 2 
software.  Isolated GFP-positive cells were quantified in the assay and approximately 60 cells 3 
were recorded for each biological replicate.  The number of cells that exhibited dye uptake was 4 
recorded as a percentage of the total number of GFP-positive cells examined and a two-way 5 
ANOVA was performed on the averages of 4 replicates.  For determining cell integrity a 6 
dextran-rhodamine-B (DR, 10 kDa, Invitrogen) uptake assay was performed. Cx30-GFP and 7 
Briefly, A88V-GFP-expressing cells were incubated in a 0.25% DR-ECS solution, as mentioned 8 
above. The number of cells that exhibited dye uptake was recorded as a percentage of the total 9 
number of GFP-positive cells and an unpaired Student’s t-test was performed on the averages of 10 
3 replicates.  Values represent the mean percentage of GFP-positive isolated cells that exhibited 11 
dye uptake ± s.e.m.   12 
 13 
TUNEL Assays   14 
 TUNEL assays were performed using an ApopTag® Red In Situ Apoptosis Detection Kit 15 
(EMD Millipore) as per the manufacturer’s instructions with a few modifications.  Briefly, 16 
control and mutant expressing cells grown in monolayer were fixed in 10% NBF, permeabilized 17 
for 10 minutes with 0.5% Triton X-100 in PBS, and subsequently washed with 1X PBS.  18 
Following the incubation period with terminal deoxynucleotidyl transferase (TdT) enzyme at 19 
37°C, cells were washed with working strength Stop/Wash buffer twice for 5 minutes each wash.  20 
Nuclei were stained with Hoescht 33342 and mounted.  Images were obtained using the Leica 21 
microscope and OpenLab Software with a 63X oil immersion objective lens.  For each biological 22 
replicate of transfected cells and controls, 10-15 images were taken of random areas.  The 23 
percentage of GFP-expressing cells that were positive for ApopTag labelling were calculated per 24 
image and a one-way ANOVA was performed on the averages of 3 biological replicates.  For 25 
untransfected and staurosporin treated controls, the number of ApopTag positive cells was 26 
recorded as a percentage of the total cell number. Values represent the mean percentage of 27 
apoptotic cells/total number of cells per image ± s.e.m.   28 
 29 
XBP-1 reverse-transcriptase (RT)-PCR splicing assay 30 
Processing of X-box binding protein 1 (XBP-1), a marker of ER stress, was detected by 1 
PCR and restriction site analysis, as described elsewhere (Williams and Lipkin, 2006). Briefly, 2 
REKs were transfected with cDNA encoding Cx30 or mutants 12-24 hrs prior to RNA 3 
extraction. As a positive control, untransfected cells were treated with the ER stress-inducing 4 
compound tunicamycin (10 µg/ml) for 4-6 hrs prior to RNA extraction. Total RNA was isolated 5 
from REKs and RT-PCR performed with RNeasy Mini and OneStep RT-PCR kits (Qiagen, 6 
Mississauga, ON), according to the manufacturer’s instructions. Briefly, 1 µg of template RNA 7 
was reverse transcribed into cDNA in the first step of the RT-PCR cycle (50oC, 30 mins) 8 
followed by amplification of the 601 bp XBP-1 product, which encompasses the 26 bp intron 9 
sequence containing the PstI restriction site, with the following primers: sense, 5’-10 
AAACAGAGTAGCAGCGCAGACTGC-3’; and antisense, 5’-11 
GGATCTCTAAAACTAGAGGCTTGGTG-3’ for 35 cycles at 94oC for 1 min, 60oC for 1 min, 12 
and 72oC for 1 min. To confirm GFP-tagged Cx30 or Cx30 mutant expression, separate RT-PCR 13 
reactions with the following primers were performed to amplify a 315 bp eGFP product: sense, 14 
5’-TCGTGACCACCCTGACCTAC-3’; and antisense, 5’-AGTTCACCTTGATGCCGTTC-3’ 15 
for 35 cycles at 94oC for 1 min, 50oC for 1 min, and 72oC for 1 min. Negative controls without 16 
RNA template were included in every experiment. To determine whether the XBP-1 products 17 
were spliced, half of the cDNA samples were incubated with PstI restriction enzymes at 37oC for 18 
2 hrs. All samples were resolved on 2% agarose gels and densitometry performed on the bands 19 
using ImageJ (http://rsb.info.nih.gov/ij/).  20 
 21 
Western Blotting 22 
 Cell lysates were collected from cultures using a Triton-based extraction buffer [1% 23 
Triton X-100 (Sigma Aldrich), 150 mM NaCl, 10 mM Tris, 1 mM EDTA, 1 mM ethylene glycol 24 
tetraacetic acid (EGTA), 0.5% nonyl phenoxypolyethoxylethanol (NP-40), 100 mM NaF, 100 25 
mM sodium orthovanadate and proteinase inhibitor mini-EDTA tablet (Roche Applied Science, 26 
Laval, QC)] adjusted to pH 7.4 as previously described by Stewart et al (2013). Extractions were 27 
repeated 3 times, and protein lysate concentrations were quantified using a bicinchoninic acid 28 
(BCA) protein determination kit (Thermo Scientific, Rockford, IL).  Total protein lysates of 50 29 
µg were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 30 
10% polyacrylamide gels and transferred to nitrocellulose membranes using the iBlot Dry 31 
Blotting System (Invitrogen).  Membranes were blocked using 5% Blotto Non-Fat Dry Milk 1 
(Santa Cruz Biotechnology) with 0.05% Tween 20 (Sigma Aldrich) in PBS (PBS-T) for 30-60 2 
mins, and subsequently incubated overnight at 4°C with rabbit anti-Cx30 (1:750-1000, 3 
Invitrogen), rabbit anti-Cx43 (1:5000, Sigma Aldrich), goat anti-GRP78 (1:500, Santa Cruz 4 
Biotechnology), mouse anti-CHOP (3 µg/mL, Abcam, Toronto, ON) and mouse anti-ATF4 (5 5 
µg/mL, Abcam) primary antibodies.  Gel loading controls included probing for the levels of β-6 
tubulin using mouse anti-β-tubulin primary antibody (1:10000, Sigma Aldrich).  Blots probed for 7 
Cx30 were counterstained with mouse anti-GFP antibodies (1:2500, EMD Millipore) to validate 8 
that the GFP tag was attached to Cx30 and Cx30 mutants.  After several washes with PBS-T, 9 
blots were then incubated with secondary anti-rabbit and anti-goat Alexa Fluor 680 (1:5000, 10 
Invitrogen) and anti-mouse IRdye 800 (1:5000, LI-COR Biosciences, Lincoln, NE) secondary 11 
antibodies for 45-60 minutes.  Following more PBS-T washes, blots were scanned and 12 
densitometry measurements were quantified using the Odyssey Infrared Imaging System (LI-13 
COR Biosciences).  Each signal was normalized to its β-tubulin loading control in the same lane, 14 
and the wild type/β-tubulin, GFP/β-tubulin or Cx30/β-tubulin outcome value was set to 1.  15 
Unpaired t-tests were performed on the fold change averages of these values from 3 distinct sets 16 
of protein lysates.  Values represent fold change ± s.e.m.   17 
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FIGURE LEGENDS 19 
 20 
Figure 1.  Cx30 mutations linked to hearing loss and skin diseases, and their differential 21 
ectopic expression in REKs.  (A) Schematic diagram of Cx30 depicting four mutations 22 
associated with hearing loss (yellow), hearing loss plus skin disease (orange) and skin disease 23 
(green).  (B) Western blot analysis was used to detect the levels of GFP-tagged Cx30 and Cx30 24 
mutants when ectopically expressed in REKs.  Blots were probed with anti-Cx30, anti-GFP or 25 
anti--tubulin antibodies.  (C) Anti-GFP labeling revealed significantly lower levels of GFP-26 
tagged V37E and A88V mutants compared to the levels of wild-type Cx30.  Values represent 27 
fold change ± s.e.m. (unpaired t-test, **P<0.01, N=3). 28 
 29 
Figure 2.  Skin disease-linked Cx30 mutants have impaired abilities to form gap junction 30 
plaques.  (A) Untransfected REKs and REKs ectopically expressing GFP-tagged Cx30 or Cx30 31 
mutants (green) were immunolabeled for protein disulfide isomerase (PDI) (red) to denote the 32 
ER.  Nuclei were stained with Hoescht 33342 (blue).  Cx30 and the T5M mutant formed 33 
punctate gap junction-like structures at the cell-to-cell interface, while V37E co-localized with 34 
PDI.  The G59R and A88V mutants were primarily localized in intracellular compartments, 35 
however a population of the mutants did reside at the cell surface (white arrows).  PDI staining 36 
was absent in A88V mutant-expressing cells, and GFP-positive cells without nuclei were dead 1 
“ghost” cells.  Scale bar = 20 µm.  (B) Immunolabeling REKs for Cx30 (green) revealed that 2 
untagged mutant expressing cells exhibited similar localization profiles as GFP-tagged mutants.  3 
Similarly, populations of the G59R and A88V mutants localized to the cell surface (arrows).  4 
Scale bar = 20 µm.  (C) REKs ectopically expressing the G59R mutant were double-labeled for 5 
Cx30 (green) and Golgi matrix protein 130 (GM130) (red), which revealed that the G59R mutant 6 
co-localized with the Golgi apparatus.  Scale bar = 20 µm.   7 
 8 
Figure 3. Effect of Cx30 mutants on endogenous Cx43 in REKs (A) Cx30- and Cx30 mutant-9 
expressing REKs (green) were immunolabeled for Cx43 (red) and stained with Hoescht 33342 10 
(blue) to denote cell nuclei.  Cx43 plaques were localized at the cell surface between REKs 11 
expressing Cx30 or the T5M and G59R mutants.  V37E- and A88V-expressing REKs did not 12 
exhibit Cx43 plaque formation between apposing cells.  Scale bar = 20 µm.  (B) Western blot 13 
analysis was used to detect total levels of Cx43 in Cx30- and mutant-expressing cells when 14 
normalized to -tubulin.  (C) Total levels of Cx43 were slightly lower in REKs expressing only 15 
the T5M hearing loss mutant and remained unchanged in V37E, G59R and A88V mutant-16 
expressing cells.  Values represent fold change ± s.e.m. (unpaired Student’s t-test, *P<0.05, 17 
N=3). 18 
 19 
Figure 4.  Skin disease-linked V37E, G59R and A88V mutants differentially affect GJIC 20 
when expressed in HeLa cells and REKs.  (A) GFP-, Cx30- and mutant-expressing HeLa cells 21 
(denoted in phase-contrast images) were imaged for the presence of GFP and microinjected with 22 
Alexa 350 dye (red asterisks).  Scale bar = 20 µm.  (B) Relative to Untr control cells, cells 23 
expressing Cx30 or the T5M mutant exhibited significantly greater incidence of dye transfer than 24 
those expressing the V37E or G59R mutants.  (C) Untr and GFP-, Cx30- and mutant-expressing 25 
REKs (denoted by phase-contrast images) were imaged for the presence of GFP and 26 
microinjected with Alexa 350 dye (red asterisks).  Scale bar = 20 µm.  (D) Relative to Untr 27 
controls, cells expressing the V37E and A88V mutants exhibited significantly lower incidences 28 
of Cx43-mediated dye transfer.  Numbers of injected cells are presented along the bottom of the 29 
panels (B, D).  Values represent the mean percent incidence of dye transfer ± s.e.m. (one-way 30 
ANOVA, **P<0.01, ***P<0.001, N=3).  Numbers of injected cells are presented along the 1 
bottom of the figure. 2 
 3 
Figure 5.  The hearing loss-linked T5M mutant exhibits hemichannel activity in HeLa cells 4 
that mimics Cx30.  (A) Single isolated Cx30- or mutant-expressing HeLa cells (denoted in 5 
phase-contrast images) were incubated with propidium iodide (PI) in normal extracellular 6 
solution (ECS) or divalent cation free-ECS (DCF-ECS).  Cells were imaged for the presence of 7 
GFP (green) and PI uptake (red).  Scale bar = 20 µm.  (B) Cells expressing the V37E and G59R 8 
mutants did not uptake PI under DCF-ECS conditions, while those expressing Cx30 or the T5M 9 
mutant exhibited significant hemichannel activity. (C) The majority of single cells expressing the 10 
A88V mutant were permeable to dextran-rhodamine (DR) under ECS conditions, indicating 11 
disruption of the cell membrane. Thus, the A88V mutant could not be used in the PI uptake 12 
assay. Values represent the mean percentage of GFP-positive isolated cells that exhibited PI or 13 
DR uptake ± s.e.m. (B, two-way ANOVA, ***P<0.001, N=4; C, Student’s t-test, ***P<0.001, 14 
N=3).   15 
 16 
Figure 6.  Ectopic expression of Clouston syndrome-linked V37E and A88V mutants 17 
induces apoptosis in REKs.  (A) TUNEL assays were performed on untransfected (Untr), GFP-, 18 
Cx30- and mutant-expressing REKs (green).  Nuclei were stained with Hoescht 33342 (blue) and 19 
apoptotic cells are indicated by ApopTag staining (red).  Staurosporine (Stauro)-treated cells 20 
served as an inducer of apoptosis.  Scale bar = 20 µm.  (B)  The expression of V37E and A88V 21 
mutants significantly induced apoptosis in REKs. (C) Treatment with staurosporine significantly 22 
induced apoptosis compared to untransfected controls.  Values represent the mean percentage of 23 
apoptotic cells/total number of cells per image ± s.e.m. (one way ANOVA, ***P<0.001, N=3). 24 
 25 
Figure 7.  Cx30 has minimal ability to rescue the trafficking of skin disease-linked mutants 26 
to the cell surface in REKs.  REKs co-expressing Cx30-RFP (red) together with GFP-tagged 27 
Cx30, T5M, V37E, G59R or A88V mutants (green) were stained with Hoescht 33342 (blue) to 28 
denote the cell nuclei.  Cx30, the T5M mutant and populations of the G59R and A88V mutants 29 
distinctly co-localized with Cx30-RFP at the cell surface.  Wild-type Cx30 minimally rescued 30 
the trafficking of V37E, G59R and A88V mutants since the majority of the protein was localized 1 
to intracellular compartments.  Scale bar = 20 µm.   2 
 3 
Figure 8.  Clouston syndrome-linked Cx30 mutants exhibit a dominant-negative effect on 4 
ectopically-expressed Cx26 in REKs.  REKs co-expressing Cx26-RFP (red) together with 5 
GFP-tagged Cx30, T5M, V37E, G59R or A88V mutants (green) were stained with Hoescht 6 
33342 (blue) to denote the cell nuclei.  Cx30, the T5M mutant and a population of the G59R 7 
mutant distinctly co-localized with Cx26-RFP at the cell surface.  Wild-type Cx26 failed to 8 
rescue trafficking of V37E and A88V mutants whereas the majority of the G59R mutant 9 
accumulated within intracellular compartments.  V37E and A88V Cx30 mutants exhibited a 10 
dominant-negative effect on wild-type Cx26, as Cx26-RFP was retained inside the cell and 11 
particularly co-localized with the A88V mutant.  Scale bar = 20 µm. 12 
 13 
Figure S1. Expression of the V37E and A88V mutants reduced the incidents of co-14 
expressed Cx43 being found in gap junctions. HeLa cells were engineered to co-express GFP-15 
tagged Cx30 and T5M, V37E, G59R and A88V mutants (green) with Cx43-RFP (red). Cx30 and 16 
T5M showed co-localization in gap junction-like plaques with Cx43. The V37E and A88V 17 
mutants showed intracellular accumulations that co-localized with Cx43 and reduced Cx43 18 
plaques were evident. The G59R mutant localized intracellularly, but it did not appear to affect 19 
the ability of Cx43 to reach the cell surface.  Scale bar = 20 µm. 20 
 21 
Figure S2.  REKs expressing V37E and A88V mutants express cleaved caspase-3.  22 
Untransfected (Untr) cells or GFP-, Cx30- and mutant-expressing REKs (green) were 23 
immunolabeled for cleaved caspase-3 (red) and nuclei were stained with Hoescht 33342 (blue).  24 
Cells expressing the V37E and A88V mutants also expressed the apoptotic marker cleaved 25 
caspase-3.  Scale bar = 20 µm. 26 
 27 
Figure S3.  Western blot analysis of the unfolded protein response in mutant-expressing 28 
REKs.  The levels of unfolded protein response (UPR) markers glucose regulated protein 78 29 
(GRP78) (A), activating transcription factor 4 (ATF4) (B) and C/EBP homologous protein 30 
(CHOP) (C) in untransfected (Untr) and GFP-, Cx30- and mutant-expressing REKs were 31 
analyzed and normalized to β-tubulin.  Protein lysates from tunicamycin (Tm)-treated cells 1 
served as an inducer of the UPR.  Blots were also probed with anti-β-tubulin antibody. 2 
Normalized values for Untr cells were set to 1. (A) In comparison to GFP-expressing cells, 3 
GRP78 expression was significantly higher in Tm-treated controls (***P<0.001) and not in cells 4 
expressing the mutants.  (B) In comparison to GFP-expressing cells, ATF4 expression was 5 
higher in V37E-expressing cells (*P<0.05) and Tm-treated controls only (**P<0.01).  (C) CHOP 6 
was also only up-regulated in Tm-treated cells only (*P<0.05 and **P<0.01).  Values represent 7 
fold change ± s.e.m. (unpaired Student’s t-test, N=3).   (D, E) Upon activation, IRE1 cleaves an 8 
intron (black box) from XBP1 mRNA to yield a spliced variant without a PstI site. The possible 9 
band sizes produced by splicing and PstI digestion are shown in the table. (F) RNA from 10 
untransfected REKs (Untr), REKs treated with tunicamycin (Tm) and REKs expressing Cx30 or 11 
Cx30 mutants was analyzed by RT-PCR using primers that amplified both the spliced (XBP1s) 12 
and unspliced (XBP1u) variants. Upper panel shows a representative gel separation of 13 
undigested and Pst1 digested bands. Note the loss of XBP1u bands (289 bp and 312 bp) and 14 
increased intensity of the XBP1s band (575 bp) for the Tm control. All other band intensities 15 
were similar between Untr and Cx30 mutants. The lower panel represents a higher resolution 16 
image of the PstI undigested bands showing the separation of XBP1u and XBP1s.  (G) 17 
Densitometry quantification and ratio of upper (575-601 bp) to lower (289-312 bp) bands 18 
showed no significant increase in XBP1 splicing for any of the mutants, whereas the Tm control 19 
significantly induced a ~3.5 fold increase in XBP1s. Values represent fold change ± s.e.m. (one 20 
way ANOVA, ***P<0.001, N=6). 21 
 22 
Figure S4.  Cx30 and Cx26 may partially rescue the trafficking of V37E and A88V mutants 23 
in HeLa cells.  HeLa cells co-expressing Cx30-RFP (red) together with GFP-tagged Cx30, T5M, 24 
V37E, G59R or A88V mutants (green) were stained with Hoescht 33342 (blue) to denote the cell 25 
nuclei.   Cx30, T5M and populations of the V37E, G59R and A88V mutants distinctly co-26 
localized with Cx30-RFP at the cell surface, however all skin disease-linked mutants were 27 
primarily intracellularly localized. HeLa cells co-expressing Cx26-RFP (red) and GFP-tagged 28 
Cx30, T5M, V37E, G59R or A88V mutants (green) were stained with Hoescht 33342 (blue) to 29 
denote the nuclei. Cx30 and T5M co-localized strongly with Cx26-RFP at the cell surface, as did 30 
the G59R mutant. There were marked reductions in Cx26-RFP gap junction plaques in both 31 
V37E and A88V expressing cells and an increase in intracellular Cx26-RFP co-localization.  1 
Scale Bars = 20 µm. 2 
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